$133.84
+1.78
(+1.35%)▲
1.61%
Downside
Day's Volatility :1.93%
Upside
0.33%
7.74%
Downside
52 Weeks Volatility :20.51%
Upside
13.85%
Period | Agilent Technologies Inc. | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | -4.73% | -7.3% | 5.9% |
6 Months | -9.7% | -0.2% | 12.5% |
1 Year | 7.06% | 9.9% | 30.9% |
3 Years | -11.99% | 8.8% | 27.0% |
Market Capitalization | 37.9B |
Book Value | $20.53 |
Dividend Share | 0.933 |
Dividend Yield | 0.73% |
Earnings Per Share (EPS) | 4.81 |
PE Ratio | 27.46 |
PEG Ratio | 2.77 |
Wall Street Target Price | 150.115 |
Profit Margin | 21.75% |
Operating Margin TTM | 24.97% |
Return On Assets TTM | 7.58% |
Return On Equity TTM | 24.66% |
Revenue TTM | 6.5B |
Revenue Per Share TTM | 22.27 |
Quarterly Revenue Growth YOY | -5.6000000000000005% |
Gross Profit TTM | 3.5B |
EBITDA | 1.6B |
Diluted Eps TTM | 4.81 |
Quarterly Earnings Growth YOY | 1.57 |
EPS Estimate Current Year | 5.24 |
EPS Estimate Next Year | 5.66 |
EPS Estimate Current Quarter | 1.26 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 12.16%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 4.9B | ↑ 9.88% |
Net Income | 316.0M | ↓ 53.8% |
Net Profit Margin | 6.43% | ↓ 8.87% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 5.2B | ↑ 5.07% |
Net Income | 1.1B | ↑ 238.92% |
Net Profit Margin | 20.74% | ↑ 14.31% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 5.3B | ↑ 3.41% |
Net Income | 719.0M | ↓ 32.87% |
Net Profit Margin | 13.47% | ↓ 7.27% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 6.3B | ↑ 18.36% |
Net Income | 1.2B | ↑ 68.29% |
Net Profit Margin | 19.15% | ↑ 5.68% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 6.8B | ↑ 8.37% |
Net Income | 1.3B | ↑ 3.64% |
Net Profit Margin | 18.31% | ↓ 0.84% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 6.8B | ↓ 0.22% |
Net Income | 1.2B | ↓ 1.12% |
Net Profit Margin | 18.15% | ↓ 0.16% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.7B | ↓ 2.22% |
Net Income | 302.0M | ↓ 14.2% |
Net Profit Margin | 17.59% | ↓ 2.46% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.7B | ↓ 2.62% |
Net Income | 111.0M | ↓ 63.25% |
Net Profit Margin | 6.64% | ↓ 10.95% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.7B | ↑ 0.96% |
Net Income | 475.0M | ↑ 327.93% |
Net Profit Margin | 28.14% | ↑ 21.5% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 1.7B | ↓ 1.78% |
Net Income | 348.0M | ↓ 26.74% |
Net Profit Margin | 20.99% | ↓ 7.15% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 1.6B | ↓ 5.13% |
Net Income | 308.0M | ↓ 11.49% |
Net Profit Margin | 19.58% | ↓ 1.41% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Revenue | 1.6B | ↑ 0.32% |
Net Income | 282.0M | ↓ 8.44% |
Net Profit Margin | 17.87% | ↓ 1.71% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 8.5B | ↑ 1.33% |
Total Liabilities | 4.0B | ↑ 10.31% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 9.5B | ↑ 10.67% |
Total Liabilities | 4.7B | ↑ 18.49% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 9.6B | ↑ 1.85% |
Total Liabilities | 4.8B | ↑ 1.06% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 10.7B | ↑ 11.2% |
Total Liabilities | 5.3B | ↑ 11.82% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 10.5B | ↓ 1.62% |
Total Liabilities | 5.2B | ↓ 1.67% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 10.8B | ↑ 2.19% |
Total Liabilities | 4.9B | ↓ 5.91% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 10.8B | ↓ 1.16% |
Total Liabilities | 5.0B | ↓ 5.63% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 10.7B | ↓ 1.08% |
Total Liabilities | 5.1B | ↑ 2.12% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 10.8B | ↑ 0.82% |
Total Liabilities | 4.9B | ↓ 3.89% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 10.9B | ↑ 1.72% |
Total Liabilities | 4.8B | ↓ 3.21% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 10.9B | ↓ 0.84% |
Total Liabilities | 4.6B | ↓ 2.48% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 11.0B | ↑ 1.29% |
Total Liabilities | 5.1B | ↑ 9.72% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.1B | ↑ 22.27% |
Investing Cash Flow | -704.0M | ↑ 130.82% |
Financing Cash Flow | -797.0M | ↑ 294.55% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.0B | ↓ 6.07% |
Investing Cash Flow | -1.6B | ↑ 125.85% |
Financing Cash Flow | -299.0M | ↓ 62.48% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 921.0M | ↓ 9.79% |
Investing Cash Flow | -147.0M | ↓ 90.75% |
Financing Cash Flow | -717.0M | ↑ 139.8% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.5B | ↑ 61.24% |
Investing Cash Flow | -749.0M | ↑ 409.52% |
Financing Cash Flow | -696.0M | ↓ 2.93% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.3B | ↓ 11.65% |
Investing Cash Flow | -338.0M | ↓ 54.87% |
Financing Cash Flow | -1.4B | ↑ 97.13% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.8B | ↑ 35.06% |
Investing Cash Flow | -310.0M | ↓ 8.28% |
Financing Cash Flow | -930.0M | ↓ 32.22% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 398.0M | ↑ 34.46% |
Investing Cash Flow | -77.0M | ↓ 25.96% |
Financing Cash Flow | -390.0M | ↑ 2194.12% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 562.0M | ↑ 41.21% |
Investing Cash Flow | -270.0M | ↑ 250.65% |
Financing Cash Flow | -322.0M | ↓ 17.44% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 516.0M | ↓ 8.19% |
Investing Cash Flow | -40.0M | ↓ 85.19% |
Financing Cash Flow | -201.0M | ↓ 37.58% |
Sell
Neutral
Buy
Agilent Technologies Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Agilent Technologies Inc. | 2.8% | -9.7% | 7.06% | -11.99% | 66.76% |
Idexx Laboratories, Inc. | -7.57% | -17.44% | -13.01% | -31.32% | 65.66% |
Thermo Fisher Scientific, Inc. | -7.42% | -10.36% | 4.72% | -19.64% | 65.25% |
Danaher Corp. | -3.89% | -8.84% | 7.2% | -27.2% | 62.72% |
Iqvia Holdings Inc. | -5.97% | -10.98% | -4.23% | -22.99% | 37.77% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Agilent Technologies Inc. | 27.46 | 27.46 | 2.77 | 5.24 | 0.25 | 0.08 | 0.01 | 20.53 |
Idexx Laboratories, Inc. | 40.32 | 40.32 | 4.41 | 10.73 | 0.59 | 0.23 | NA | 19.72 |
Thermo Fisher Scientific, Inc. | 32.36 | 32.36 | 1.95 | 21.69 | 0.13 | 0.05 | 0.0 | 128.08 |
Danaher Corp. | 44.43 | 44.43 | 2.74 | 7.5 | 0.08 | 0.04 | 0.0 | 71.03 |
Iqvia Holdings Inc. | 26.52 | 26.52 | 1.03 | 11.14 | 0.22 | 0.05 | NA | 38.37 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Agilent Technologies Inc. | Buy | $37.9B | 66.76% | 27.46 | 21.75% |
Idexx Laboratories, Inc. | Buy | $34.3B | 65.66% | 40.32 | 22.53% |
Thermo Fisher Scientific, Inc. | Buy | $197.4B | 65.25% | 32.36 | 14.48% |
Danaher Corp. | Buy | $169.8B | 62.72% | 44.43 | 16.39% |
Iqvia Holdings Inc. | Buy | $36.6B | 37.77% | 26.52 | 9.17% |
Insights on Agilent Technologies Inc.
Revenue is up for the last 2 quarters, 1.57B → 1.57B (in $), with an average increase of 0.3% per quarter
Netprofit is down for the last 4 quarters, 475.0M → 282.0M (in $), with an average decrease of 15.6% per quarter
In the last 1 year, Danaher Corp. has given 6.5% return, outperforming this stock by 0.8%
Vanguard Group Inc
BlackRock Inc
Massachusetts Financial Services Company
State Street Corp
Wellington Management Company LLP
Morgan Stanley - Brokerage Accounts
In the quarter ending September,2024. Agilent Technologies Inc. has declared dividend of $0.24
Read Moreanalytical scientists and clinical researchers worldwide rely on agilent to help fulfill their most complex laboratory demands. our instruments, software, services and consumables address the full range of scientific and laboratory management needs—so our customers can do what they do best: improve the world around us. whether a laboratory is engaged in environmental testing, academic research, medical diagnostics, pharmaceuticals, petrochemicals or food testing, agilent provides laboratory solutions to meet their full spectrum of needs. we work closely with customers to help address global trends that impact human health and the environment, and to anticipate future scientific needs. our solutions improve the efficiency of the entire laboratory, from sample prep to data interpretation and management. customers trust agilent for solutions that enable insights...for a better world.
Organization | Agilent Technologies Inc. |
Employees | 17400 |
CEO | Mr. Padraig McDonnell |
Industry | Health Technology |